Cobimetinib CAS No:934660-93-2

Product Detail

PRODUCT NAME	Cobimetinib
CAS No.:	934660-93-2
Synonyms	[3,4-Difluoro-2-[(2-fluoro-4-iodophenyl)amino]phenyl][3-hydroxy-3-(2S)-2-piperidinyl-1-azetidinyl]methanone
	GDC 0973;XL 518;
Formula:	C21H21F3IN3O2	Molecular Weight:	531.31000
PSA:	64.60000	LogP:	4.12080

Structure:
  

Description: 


Cobimetinib (trade name Cotellic) is a MEK inhibitor developed by Exelixis and Genentech. It is used in combination with vemurafenib, a BRAF inhibitor, to treat melanoma. In November 2015, the U.S. Food and Drug Administration approved cobimetinib for unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib (Zelboraf). Cobimetinib is not indicated for treatment of patients with wild-type BRAF melanoma.
Cobimetinib in combination with vemurafenib is reportedly priced at $17,600 per month, or about $211,000 per year. A competing dual therapy, using dabrafenib along with trametinib, is also approved by the FDA, and is reported to cost $15,300 monthly, or $183,600 per year.
We can provide this product with purity 99%.




The test result of COA

ProductName: Cobimetinib

Cas:       934660-93-2

Batch No.:    20171012

MFG Date:  Oct.12.2017

Analysis Date:Oct.12.2017

 

 

 

Inspect Item	Quantity Standard	Inspection Result
Appearance	White to light   yellow powder	White powder
Identification	Positive	Conforms
Purity	98%	99.40%
Single impurity	0.20%	0.33%
Residual solvent	0.50%	0.30%
EE value	99%	99.82%
Conclusion	In accordance with enterprise standard